Ihre Browserversion ist veraltet. Wir empfehlen, Ihren Browser auf die neueste Version zu aktualisieren.

Latest News

Jan 15, 2021: - EQIPD has recorded a series of lectures introducing its novel Quality System - Youtube

Dec 17, 2020: EQIPD-based tool is released to support research collaborations - full text

Sep 12-15, 2020: EQIPD's stand at the 33rd ECNP Congress (virtual!) - about congress

Jul 22, 2020: EQIPD releases a white paper describing its newly developed  quality system - open access

Feb 27, 2020: Book on quality in preclinical research co-authored by EQIPD members has just been published - open access

Our Vision

Simple and sustainable solutions that facilitate improvements in data quality
without impacting innovation and freedom of research.


EQIPD supports every member of the research community

Pharma industry

… invests into the most expensive phases of drug R&D.

Clinical studies based on preclinical evidence lacking robustness are likely to fail.

Private and public funders

… support a great number of projects guided by their scientific excellence. 

Research quality assessment is a filter that can be applied to focus investments on most robust and therefore more likely to translate research. 

Research organizations

… increasingly depend on successful collaborations and sustainability of research output.

EQIPD offers several possibilities to review, implement and maintain best research practices.

Defining where EQIPD is active and makes an impact

Scientific Excellence vs.
Research Quality

Scientific excellence is the key to advance science but it does not guarantee that the conducted experiments deliver robust results. There are two primary reasons for that.

First, education in science does not always focus on the requirements for delivering of robust data.

Second, excitement associated with a scientific hypothesis or conveyed by a scientific leader may introduce bias in study design, conduct, analysis and/or reporting.

Regulated vs. Non-regulated

In the drug discovery and development process, there are several steps that have adequate quality control and are covered by GxP policies (e.g. Good Laboratory Practice, GLP).

For non-regulated areas (most specifically, biology and pharmacology of drug discovery projects), GLP-like procedures would not be fit for purpose and may not help to secure the quality of research. In fact, one may indeed imagine a lab running under GLP conditions but nevertheless still failing to design and execute robust studies.

Good Research Practice vs
Research Integrity

Responsible conduct of research has multiple facets and the examples of suboptimal or unacceptable practices go well beyond the commonly known definition of research misconduct (fabrication, falisfication or plagiarism).

In addition to such direct violations of the good research practices, examples of other unacceptable practices include manipulating authorship, withholding research results, reporting of results so as to introduce or promulgate bias, failing to document essential steps or results of the research process.

EQIPD is concerned with general principles of research quality.

While the initial focus was on preclinical drug discovery, EQIPD results apply to biomedical research in general and may even extend to areas of research beyond life sciences.

EQIPD develops and promotes solutions for non-regulated areas of research (and, in particular, for drug discovery), such as the EQIPD Quality System and the EQIPD recommendations on Good Research Practice in study design,  conduct, analysis and reporting. 

EQIPD supports every aspect of responsible conduct of research and is collaborating with research integrity professionals to develop solutions that address the challenges at the border of traditional research integrity and good research practice fields.

Cookie Policy

This site uses cookies to store information on your computer.

Do you accept?